Shares of A.P. Pharma Inc. (OTC: APPA), a specialty pharmaceutical company engaged in the development of pharmaceutical products using its Biochronomer polymer-based drug delivery technology, are up sharply in trading currently.
At last check, APPA shares were trading 6.20% higher at $0.685 on above average volume of 183,678. The stock gained 16.52% in the last three trading sessions.
A.P. Pharma recently announced that an abstract examining a subset of efficacy results from its Phase 3 trial of APF 530 has been published in conjunction with the American Society of Clinical Oncology’s (ASCO) 2012 Annual Meeting. APF530, which is A.P. Pharma’s lead product candidate, is being developed for the prevention of acute-and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
Recent Comments